Following the experiences that have been taking place in the recent weeks, we consider important to share the second update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe COVID-19 infection.

This document is for informative purposes only for clinicians who decide to undertake this type of therapy.

In this particularly critical moment, Aferetica wants to send its thoughts and wishes good work to the whole medical-scientific community, engaged in the front line in the fight against Coronavirus Covid-19.